SINNOVIAL

SiNNOViAL

One line pitch:
Develop & provide online predictive orientation test (theranostic) to assist medical staff in therapeutic choice for chronic inflammatory disease(CID)

Market Analysis:
Chronic Inflammatory Diseases (CID) affects about 1 million people per year around the world. Almost 40% are treated by biotherapies. Biotherapies : France: 2 billion €/ year; Rheumatology: 800 million €/ year Europe: 20 billion €/ year; Rheumatology: 8 billion €/ year WW: 180 billion €/ year; Rheumatology: 65 billion €/ year This market is significant growth of 10-15% per year. Through our strong presence in the hospital sector, our "action area" focuses primarily on the first hospital prescriptions, when the patient comes to visit his rheumatologist for confirmation of his illness and the first choice of biotherapy. Thereafter we will open access to our technology to all rheumatologists.

Value proposition:
Today, 33% of the patients treated by biotherapies for CID are not responding to their treatment. Furthermore, biotherapies are expensive (10-15k€/year/patient) with a slow biological start-up (4-6 months)! This non-response represents a significant deterioration in the patient's physical condition and an important cost for the health system. Our technology, based on proteomic analysis, allows optimizing the chronic diseases treatment in rheumatology by determining before the prescription, if the molecule prescribed by the physician will be operational within the patient. So, we are able to improve the health care system by optimization of CID supports and provide a better efficacy of treatment.

Business Model:
Today, rheumatologist doesn't have tool or clinical proof to determine the best treatment for his patient among the 9 biotherapies available (4 new biotherapies coming soon). The health-authorities want to oblige the pharmaceutical companies to adopt the new technologies for a personalized medicine and cost effectiveness. Our Business model is to provide our online predictive test to the rheumatologist and deal with pharmaceutical companies which would promote their biotherapies by our new predictive-test (several collaboration ongoing). These companies will assume the cost of providing this analyze to physicians and our royalties ("Google" model), to increase confidence of their biotherapies.

IP and Regulatory situation:
A patent (about methodology) was registered in 2013 by the innovation district of Université Grenoble Alpes (Floralis). Sinnovial SAS obtained a full exclusive license on March 2016. The secret know-how (biological analysis & algorithm) generated during the last 7 years is strictly protected in-house. Regarding the regulatory situation, we decided to work with the company SQI, which is specialized in graphical online interface development and his regulatory validation (CE & FDA). Our fisrt predictive-test will be available for French and European rhumatologist around Q1-2017.

COMPANY PROFILE

- **Website:**
  www.sinnovial.com
- **Field:**
- **Contact:**
  GIROD-ROUX Pierre-Marie
  pm.girod-roux@sinnovial.com
- **Location:**
  29 rue de la Paix
  38180 Seyssins
  France
- **Founded in:** //09/2015
- **Employees:** 5

- **Financial information (€):**
  - **Company stage:**
  Pilot Phase
  - **Capital raised to date:**
  450k
  - **Monthly burn rate:**
  40k
  - **Capital seeking and date:**
  300-500k€Q1-2017
- **Investors:**
  Gaudin Philippe , Baillet Athan , Girod-Roux Pierre-Marie , Floralis - UGA